InflaRx to Showcase Innovations at Upcoming Investor Events
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company dedicated to developing groundbreaking anti-inflammatory therapies by targeting the complement system, has announced its participation in two significant investor conferences in September 2024. This involvement underscores the company’s dedication to sharing its progress and strategic vision with investors.
Details of the Upcoming Conferences
InflaRx will take part in the H.C. Wainwright 26th Annual Global Investment Conference, which runs from September 9 to 11. During this event, the company will offer an on-demand virtual presentation starting on September 9, enabling investors to engage with its innovations from anywhere. Additionally, InflaRx representatives will hold one-on-one meetings with investors in New York City on September 10. This format not only allows for direct interaction with investors but also fosters opportunities for partnership discussions.
Fireside Chat at the Cantor Conference
After the H.C. Wainwright conference, InflaRx will also be featured at the 2024 Cantor Global Healthcare Conference, taking place from September 17 to 19. A key highlight of this event will be InflaRx's fireside chat scheduled for September 18 at 9:45 AM ET, where prominent company representatives will discuss strategic innovations and their potential impact on the healthcare sector. On the same day, the company will conduct one-on-one meetings with investors, further emphasizing its commitment to open dialogue and collaboration.
Innovative Therapeutics by InflaRx
InflaRx is recognized for its cutting-edge research and development of anti-inflammatory therapeutics. The company leverages its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize effective inhibitors that target the complement activation factor C5a and its receptor C5aR. These advancements are particularly crucial for tackling a wide range of inflammatory diseases, placing InflaRx at the forefront of therapeutic innovation in this field.
Lead Product Candidate
The lead product candidate, vilobelimab, is a first-in-class monoclonal antibody that exhibits promising clinical activity. This treatment, delivered intravenously, selectively binds to free C5a, demonstrating beneficial disease-modifying effects and good tolerability across various clinical studies involving multiple indications. Additionally, InflaRx is developing INF904, an orally administered small molecule aimed at inhibiting the C5a receptor, marking another significant step in its innovative pipeline.
Company Background and Contact Information
Founded in 2007, InflaRx has built a strong presence in both Germany and the USA, strategically positioning itself for research and collaboration opportunities. With offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, the company has expanded its influence within the biopharmaceutical sector.
For inquiries related to investor relations, interested parties can contact:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What types of conferences is InflaRx participating in?
InflaRx will participate in the H.C. Wainwright 26th Annual Global Investment Conference and the 2024 Cantor Global Healthcare Conference.
When is InflaRx's fireside chat scheduled?
The fireside chat at the Cantor Global Healthcare Conference is scheduled for September 18 at 9:45 AM ET.
What is InflaRx's lead product candidate?
InflaRx's lead product candidate is vilobelimab, an anti-C5a monoclonal antibody that shows promise in treating inflammatory diseases.
Where is InflaRx located?
InflaRx has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.
How can investors contact InflaRx?
Investors can reach out to InflaRx's investor relations through Jan Medina at IR@inflarx.de or through the contact details provided for MC Services AG.
